(Q38058979)

27 August 2017

title

Primary biliary cirrhosis and bile acids (English)

1 reference

primary biliary cholangitis

27 August 2017

main subject

0 references

author name string

Christophe Corpechot

series ordinal

1

1 reference

27 August 2017

language of work or name

1 reference

1 September 2012

1 reference

Clinics and research in hepatology and gastroenterology

27 August 2017

published in

1 reference

27 August 2017

volume

36 Suppl 1

1 reference

27 August 2017

page(s)

S13-20

1 reference

Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Effect of chronic administration of ursodeoxycholic acid on the ileal absorption of endogenous bile acids in man

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Effect of ursodeoxycholic acid treatment on ileal absorption of bile acids in man as determined by the SeHCAT test

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Assessment of biliary bicarbonate secretion in humans by positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Suppressive effect of ursodeoxycholic acid on type IIA phospholipase A2 expression in HepG2 cells

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Survival in ursodeoxycholic acid-treated patients with biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg. Dutch Multicentre PBC Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Ursodeoxycholic acid in the treatment of primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Survival of anti-mitochondrial antibody-positive and -negative primary biliary cirrhosis patients on ursodeoxycholic acid treatment

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

UDCA, PBC, and biochemistry, what does normal mean?

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Time course of histological progression in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Transplantation trends in primary biliary cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Geotherapeutics of primary biliary cirrhosis: bright and sunny around the Mediterranean but still cloudy and foggy in the United Kingdom

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Trends in liver transplantation for primary biliary cirrhosis in the Netherlands 1988-2008.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Serum bilirubin: a prognostic factor in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Biochemical response to ursodeoxycholic acid predicts long-term outcome in Japanese patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Improved liver tests and greater biliary enrichment with high dose ursodeoxycholic acid in early stage primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

EASL Clinical Practice Guidelines: management of cholestatic liver diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Systematic review: ursodeoxycholic acid--adverse effects and drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Treatment with ursodeoxycholic acid is associated with weight gain in patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

The long-term effect of ursodeoxycholic acid on laboratory liver parameters in biochemically non-advanced primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Characterisation of patients with a complete biochemical response to ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Pregnancy in women with ursodeoxycholic acid-treated primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Chronic diarrhea due to excessive bile acid synthesis and not defective ileal transport: a new syndrome of defective fibroblast growth factor 19 release

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO⁻₃ output

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970016-5

7 January 2021

10.1016/S2210-7401(12)70016-5

Identifiers

DOI

1 reference

27 August 2017

1 reference